Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from Loyola University Chicago in the area of breast cancer published
October 2nd, 2008
" The objective of this phase III global study was to compare the efficacy of gemcitabine plus paclitaxel (GT) versus paclitaxel in patients with advanced breast cancer. It was designed as a pivotal study for the approval of G for a breast cancer treatment indication," researchers in the United States report. "Patients and Methods Patients who relapsed after adjuvant anthracyclines were randomly assigned to gemcitabine, 1,250 mg/m(2) days 1 and 8 plus paclitaxel, 175 mg/m2 on day 1; or, to paclitaxel at same dose on day 1 (both arms administered every 21 days, unblinded). The primary end point was overall survival ( OS) and secondary end points were time to progression...
Source: Women's Health Weekly (2008-10-02)
|
